Oppenheimer Maintains Outperform Rating On China Nuokang Bio-Pharmaceutical Inc. (NKBP)

Analysts Katherine Lu and Carolyn Qiu at Oppenheimer have maintained their Outperform rating on China Nuokang Bio-Pharmaceutical Inc. NKBP. The company delivered another solid quarter, with revenue and EPS coming in ahead of analysts’ and consensus estimates. Analysts say that the company’s risk/reward profile remains favorable due to:

• the strong growth perspective of China’s hemacoagulase market,
• the company’s specialty sales force to distribute additional in-licensing products,
• and the fact that the stock is currently trading at just 7.9x analysts’ 2010 EPS estimate ex-cash.